Ctla4 antibody combination therapy

Details Ctla4 antibody combination therapy Ctla4 antibody combination therapy

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61P 31/18 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2647282

The invention relates to administration of an anti-CTLA4 antibody, particularly human antibodies to human CTLA4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, CP-675,206 (11.2.1), and ipilimumab, in combination with a therapeutic agent for treatment of cancer. An exemplary method of the invention comprises administering an anti-CTLA4 antibody, preferably, CP-675,206, and a chemotherapeutic agent, preferably, gemcitabine, for treatment of pancreatic cancer, among other treatment modalities.

L'invention concerne l'administration d'un anticorps anti-CTLA4, en particulier d'anticorps humains dirigés contre le CTLA4 humain, tels que ceux comportant les séquences d'acides aminés des anticorps 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, CP-675,206 (11.2.1) et ipilimumab, en association avec un agent thérapeutique pour traiter le cancer. Un procédé selon l'invention donné à titre d'exemple consiste à administrer un anticorps anti-CTLA4, de préférence le CP-675,206, et un agent chimiothérapeutique, de préférence la gemcitabine, pour traiter le cancer du pancréas, parmi d'autres modalités de traitement.

Affiliated with

Also associated with

Rating

Ctla4 antibody combination therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ctla4 antibody combination therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ctla4 antibody combination therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1922323